MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer

Friday, June 2, 2023 - 19:33 in Health & Medicine

MEDSIR announced today the positive results of the PHERGain trial. This study is the first to use an adaptive design that tailors treatment in the neoadjuvant/adjuvant setting of patients with HER2-positive early breast cancer. The main objective of this trial was to assess the feasibility of a chemotherapy-free strategy based on a dual HER2 blockade with trastuzumab and pertuzumab through a positron emission tomography (PET)-based, pathologic complete response response(pCR)-adapted strategy.

Read the whole article on Newswise - Scinews

More from Newswise - Scinews

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net